{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:27:49Z","timestamp":1793978869760,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007956","name":"Nanjing University of Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404406"],"award-info":[{"award-number":["82404406"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119246","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T14:11:12Z","timestamp":1786889472000},"page":"119246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Optimization of covalent pan-fibroblast growth factor receptor inhibitors for treating solid tumors"],"prefix":"10.1016","volume":"319","author":[{"given":"Shihe","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuihua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaomei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119246_bib1","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","article-title":"Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer","volume":"18","author":"Brooks","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119246_bib2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.critrevonc.2017.02.018","article-title":"FGFR a promising druggable target in cancer: molecular biology and new drugs","volume":"113","author":"Porta","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2026.119246_bib3","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119246_bib4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119246_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/BJ20101603","article-title":"Fibroblast growth factors and their receptors in cancer","volume":"437","author":"Wesche","year":"2011","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2026.119246_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.drudis.2013.07.021","article-title":"Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations","volume":"19","author":"Ho","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119246_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.860985","article-title":"Signaling pathway and small-molecule drug discovery of FGFR: a comprehensive review","volume":"10","author":"Zheng","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2026.119246_bib8","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.4155\/fmc-2022-0194","article-title":"Targeting FGFRs for tumor therapy: current status and novel strategies","volume":"14","author":"Dong","year":"2022","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119246_bib9","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119246_bib10","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1039\/C9MD90044F","article-title":"A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA","volume":"10","author":"Murray","year":"2019","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2026.119246_bib11","doi-asserted-by":"crossref","first-page":"10666","DOI":"10.1021\/acs.jmedchem.1c00713","article-title":"Discovery of pemigatinib: a potent and selective fibroblast growth factor receptor (FGFR) inhibitor","volume":"64","author":"Wu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119246_bib12","article-title":"INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119246_bib13","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119246_bib14","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.119246_bib15","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.21873\/anticanres.17046","article-title":"Antitumor activity of tasurgratinib as an orally available FGFR1-3 inhibitor in cholangiocarcinoma models with FGFR2-fusion","volume":"44","author":"Kawano","year":"2024","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2026.119246_bib16","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS3157","article-title":"FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusionpositive advanced solid tumors irrespectively of tumor histology","volume":"37","author":"Hyman","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119246_bib17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1200\/JCO.21.02303","article-title":"FORT-1: phase II\/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1\/3 mRNA expression","volume":"41","author":"Sternberg","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119246_bib18","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s40265-021-01567-1","article-title":"Infigratinib: first approval","volume":"81","author":"Kang","year":"2021","journal-title":"Drugs"},{"issue":"13","key":"10.1016\/j.ejmech.2026.119246_bib19","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1158\/1538-7445.AM2021-1012","article-title":"Abstract 1012: in vitro antitumor effect of AZD4547 in ovarian cancer cell lines","volume":"81","author":"Seo","year":"2021","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119246_bib20","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/cpt.2752","article-title":"Integration of pharmacokinetics, pharmacodynamics, safety, and efficacy into model-informed dose selection in oncology first-in-human study: a case of Roblitinib (FGF401)","volume":"112","author":"Wilbaux","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119246_bib21","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-Human phase I study of Fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.119246_bib22","doi-asserted-by":"crossref","first-page":"8858","DOI":"10.1021\/acs.jmedchem.3c00455","article-title":"Discovery and structural optimization of novel quinolone derivatives as potent irreversible pan-fibroblast growth factor receptor inhibitors for treating solid tumors","volume":"66","author":"Hu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119246_bib23","doi-asserted-by":"crossref","first-page":"13572","DOI":"10.1021\/acs.jmedchem.3c01927","article-title":"Exploring 2-Sulfonylpyrimidine warheads as acrylamide surrogates for targeted covalent inhibition: a BTK story","volume":"67","author":"Moraru","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119246_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1021\/acsmedchemlett.7b00485","article-title":"2-Formylpyridyl ureas as highly selective reversible-covalent inhibitors of fibroblast growth factor receptor 4","volume":"9","author":"Knoepfel","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119246_bib25","article-title":"Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors","author":"Buschmann","year":"2016","journal-title":"U.S. Patent"},{"key":"10.1016\/j.ejmech.2026.119246_bib26","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","article-title":"Ponatinib (AP24534), a multi-targeted Pan-FGFR inhibitor with activity in multiple FGFR amplified or mutated cancer models","volume":"11","author":"Gozgit","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119246_bib27","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1021\/jm070562u","article-title":"Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases","volume":"50","author":"Graczyk","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119246_bib28","series-title":"Pyrimidine FGFR4 Inhibitors","author":"Reynolds","year":"2015"},{"key":"10.1016\/j.ejmech.2026.119246_bib29","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0731-7085(98)00010-7","article-title":"Multiwavelength spectrophotometric determination of acid dissociation constants of ionizable drugs","volume":"17","author":"Allen","year":"1998","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2026.119246_bib30","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1021\/acs.jcim.0c00154","article-title":"Discovery of ubiquitin-specific protease 7 (USP7) inhibitors with novel scaffold structures by virtual screening, molecular dynamics simulation, and biological evaluation","volume":"60","author":"Liu","year":"2020","journal-title":"J. Chem. Inf. Model."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:02:18Z","timestamp":1793977338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":30,"alternative-id":["S0223523426006914"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119246","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of covalent pan-fibroblast growth factor receptor inhibitors for treating solid tumors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119246"}}